Short Interest in Humacyte, Inc. (NASDAQ:HUMAW) Expands By 216.3%

Humacyte, Inc. (NASDAQ:HUMAW) was the target of a significant increase in short interest in February. As of February 13th, there was short interest totaling 3,992 shares, an increase of 216.3% from the January 29th total of 1,262 shares. Based on an average daily trading volume, of 27,514 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 27,514 shares, the days-to-cover ratio is currently 0.1 days.

Humacyte Stock Performance

Shares of HUMAW opened at $0.11 on Thursday. Humacyte has a 12-month low of $0.08 and a 12-month high of $1.23. The company has a 50-day moving average of $0.12 and a two-hundred day moving average of $0.18.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.